ABSTRACT
The primary outcome was to evaluate statin use in COVID-19 critically ill patients and its association with mortality;other outcomes were considered secondary. B Conclusions: b The use of statin as adjunctive therapy in COVID-19 critically ill patients may have a beneficial role and survival benefits with a good safety profile. B Background: b Severe Corona Virus Disease 2019 (COVID-19) can heighten the systematic inflammatory response in critically ill patients, causing a systemic hyperinflammatory state leading to multiple complications. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)